{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:07:01Z","timestamp":1789826821453,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japan Research Foundation Clinical Pharmacology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"DOI":"10.1007\/s10147-026-03201-0","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:16:23Z","timestamp":1789823783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5914-504X","authenticated-orcid":false,"given":"Masahiro","family":"Hatori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Arafune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4682-4369","authenticated-orcid":false,"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-128X","authenticated-orcid":false,"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2023-1300","authenticated-orcid":false,"given":"Kazuyoshi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":false,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0672-7214","authenticated-orcid":false,"given":"Naoki","family":"Sasahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-1970","authenticated-orcid":false,"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3295-4867","authenticated-orcid":false,"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4436-0529","authenticated-orcid":false,"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"6","key":"3201_CR1","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10(6):427\u2013437. https:\/\/doi.org\/10.1634\/theoncologist.10-6-427","journal-title":"Oncologist"},{"issue":"9","key":"3201_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/s1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C et al (2005) Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 6(9):669\u2013677. https:\/\/doi.org\/10.1016\/s1470-2045(05)70255-2","journal-title":"Lancet Oncol"},{"issue":"10","key":"3201_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1038\/sj.bjc.6601366","volume":"89","author":"DA Cameron","year":"2003","unstructured":"Cameron DA, Massie C, Kerr G et al (2003) Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 89(10):1837\u20131842. https:\/\/doi.org\/10.1038\/sj.bjc.6601366","journal-title":"Br J Cancer"},{"issue":"8","key":"3201_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00228-017-2260-0","volume":"73","author":"A Otake","year":"2017","unstructured":"Otake A, Tsuji D, Taku K et al (2017) Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine. Eur J Clin Pharmacol 73(8):1033\u20131039. https:\/\/doi.org\/10.1007\/s00228-017-2260-0","journal-title":"Eur J Clin Pharmacol"},{"key":"3201_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10110454","author":"Y Yamada","year":"2018","unstructured":"Yamada Y, Fujii H, Watanabe D et al (2018) Severe neutropenia is associated with better clinical outcomes in patients with advanced pancreatic cancer who receive modified FOLFIRINOX therapy. Cancers. https:\/\/doi.org\/10.3390\/cancers10110454","journal-title":"Cancers"},{"issue":"1","key":"3201_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3727\/096504012x13425470196137","volume":"20","author":"JS Ryu","year":"2012","unstructured":"Ryu JS, Kim HJ, Shin ES et al (2012) Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin. Oncol Res 20(1):25\u201330. https:\/\/doi.org\/10.3727\/096504012x13425470196137","journal-title":"Oncol Res"},{"issue":"1","key":"3201_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-011-1670-4","volume":"69","author":"M Joerger","year":"2012","unstructured":"Joerger M, Burgers JA, Baas P et al (2012) Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin\/gemcitabine. Cancer Chemother Pharmacol 69(1):25\u201333. https:\/\/doi.org\/10.1007\/s00280-011-1670-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"3201_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/11532970-000000000-00000","volume":"49","author":"E Sugiyama","year":"2010","unstructured":"Sugiyama E, Kaniwa N, Kim SR et al (2010) Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet 49(8):549\u2013558. https:\/\/doi.org\/10.2165\/11532970-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3201_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/jco.2006.06.7405","volume":"25","author":"E Sugiyama","year":"2007","unstructured":"Sugiyama E, Kaniwa N, Kim SR et al (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25(1):32\u201342. https:\/\/doi.org\/10.1200\/jco.2006.06.7405","journal-title":"J Clin Oncol"},{"issue":"7","key":"3201_CR10","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1158\/1078-0432.Ccr-04-1497","volume":"11","author":"K Yonemori","year":"2005","unstructured":"Yonemori K, Ueno H, Okusaka T et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11(7):2620\u20132624. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-04-1497","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3201_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100019","volume":"6","author":"B Pellegrino","year":"2021","unstructured":"Pellegrino B, Cavanna L, Boggiani D et al (2021) Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). ESMO Open 6(1):100019. https:\/\/doi.org\/10.1016\/j.esmoop.2020.100019","journal-title":"ESMO Open"},{"issue":"6","key":"3201_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1634\/theoncologist.12-6-622","volume":"12","author":"SY Rha","year":"2007","unstructured":"Rha SY, Jeung HC, Choi YH et al (2007) An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. Oncologist 12(6):622\u2013630. https:\/\/doi.org\/10.1634\/theoncologist.12-6-622","journal-title":"Oncologist"},{"issue":"22","key":"3201_CR13","doi-asserted-by":"publisher","first-page":"5325","DOI":"10.1002\/cncr.25282","volume":"116","author":"M Tanaka","year":"2010","unstructured":"Tanaka M, Javle M, Dong X et al (2010) Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116(22):5325\u20135335. https:\/\/doi.org\/10.1002\/cncr.25282","journal-title":"Cancer"},{"issue":"1","key":"3201_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/1078-0432.Ccr-09-1555","volume":"16","author":"T Okazaki","year":"2010","unstructured":"Okazaki T, Javle M, Tanaka M et al (2010) Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 16(1):320\u2013329. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-09-1555","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3201_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/fpc.0000000000000375","volume":"29","author":"F Innocenti","year":"2019","unstructured":"Innocenti F, Jiang C, Sibley AB et al (2019) An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance). Pharmacogenet Genomics 29(6):123\u2013131. https:\/\/doi.org\/10.1097\/fpc.0000000000000375","journal-title":"Pharmacogenet Genomics"},{"issue":"12","key":"3201_CR16","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2217\/pgs.14.107","volume":"15","author":"JK Lamba","year":"2014","unstructured":"Lamba JK, Fridley BL, Ghosh TM et al (2014) Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15(12):1565\u20131574. https:\/\/doi.org\/10.2217\/pgs.14.107","journal-title":"Pharmacogenomics"},{"issue":"21","key":"3201_CR17","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1200\/jco.2008.20.8793","volume":"27","author":"DR Gandara","year":"2009","unstructured":"Gandara DR, Kawaguchi T, Crowley J et al (2009) Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 27(21):3540\u20133546. https:\/\/doi.org\/10.1200\/jco.2008.20.8793","journal-title":"J Clin Oncol"},{"issue":"10","key":"3201_CR18","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.clinthera.2025.07.012","volume":"47","author":"NG Torso","year":"2025","unstructured":"Torso NG, Matos YG, Fidelis GFS et al (2025) Genetic polymorphisms as treatment biomarkers for gynecological malignancies treated with carboplatin and paclitaxel: a systematic review. Clin Ther 47(10):904\u2013917. https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.012","journal-title":"Clin Ther"},{"issue":"10","key":"3201_CR19","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1002\/jps.22680","volume":"100","author":"H Gr\u00e9en","year":"2011","unstructured":"Gr\u00e9en H, Khan MS, Jakobsen-Falk I et al (2011) Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel\/carboplatin-induced myelosuppression in patients with ovarian cancer. J Pharm Sci 100(10):4205\u20134209. https:\/\/doi.org\/10.1002\/jps.22680","journal-title":"J Pharm Sci"},{"issue":"2","key":"3201_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1742-7843.2011.00802.x","volume":"110","author":"TK Bergmann","year":"2012","unstructured":"Bergmann TK, Brasch-Andersen C, Gr\u00e9en H et al (2012) Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 110(2):199\u2013204. https:\/\/doi.org\/10.1111\/j.1742-7843.2011.00802.x","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3201_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-015-0001-5","volume":"16","author":"S Lambrechts","year":"2015","unstructured":"Lambrechts S, Lambrechts D, Despierre E et al (2015) Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol 16:2. https:\/\/doi.org\/10.1186\/s40360-015-0001-5","journal-title":"BMC Pharmacol Toxicol"},{"issue":"17","key":"3201_CR22","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","volume":"42","author":"TM Sissung","year":"2006","unstructured":"Sissung TM, Mross K, Steinberg SM et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42(17):2893\u20132896. https:\/\/doi.org\/10.1016\/j.ejca.2006.06.017","journal-title":"Eur J Cancer"},{"issue":"18","key":"3201_CR23","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.Ccr-13-0487","volume":"19","author":"AJ de Graan","year":"2013","unstructured":"de Graan AJ, Elens L, Smid M et al (2013) A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin Cancer Res 19(18):5210\u20135217. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0487","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3201_CR24","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bcp.16359","volume":"91","author":"A Maeda","year":"2025","unstructured":"Maeda A, Matsuo K, Ando H et al (2025) Impact of ABCB1 single-nucleotide variants on early, extremely severe neutropenia induced by paclitaxel\/nanoparticle albumin-bound paclitaxel in patients with gastric cancer. Br J Clin Pharmacol 91(4):1216\u20131222. https:\/\/doi.org\/10.1111\/bcp.16359","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3201_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s10637-022-01275-x","volume":"40","author":"M Horiuchi","year":"2022","unstructured":"Horiuchi M, Uemura T, Oguri T et al (2022) Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Invest New Drugs 40(5):934\u2013943. https:\/\/doi.org\/10.1007\/s10637-022-01275-x","journal-title":"Invest New Drugs"},{"issue":"7","key":"3201_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","volume":"67","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Gr\u00e9en H, Brasch-Andersen C et al (2011) Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67(7):693\u2013700. https:\/\/doi.org\/10.1007\/s00228-011-1007-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"3201_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1177\/0091270005276204","volume":"45","author":"M Nakajima","year":"2005","unstructured":"Nakajima M, Fujiki Y, Kyo S et al (2005) Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45(6):674\u2013682. https:\/\/doi.org\/10.1177\/0091270005276204","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"3201_CR28","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1111\/cas.70087","volume":"116","author":"G Kanesada","year":"2025","unstructured":"Kanesada G, Tsunedomi R, Nakagami Y et al (2025) The C11orf24 gene as a useful biomarker for predicting severe neutropenia in modified FOLFIRINOX for pancreatic cancer. Cancer Sci 116(7):2008\u20132019. https:\/\/doi.org\/10.1111\/cas.70087","journal-title":"Cancer Sci"},{"issue":"2","key":"3201_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1634\/theoncologist.2014-0394","volume":"20","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Chiorean EG, Infante JR et al (2015) Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Oncologist 20(2):143\u2013150. https:\/\/doi.org\/10.1634\/theoncologist.2014-0394","journal-title":"Oncologist"},{"issue":"11","key":"3201_CR30","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jjco\/hyn098","volume":"38","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Ikeda M, Okusaka T et al (2008) Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 38(11):755\u2013761. https:\/\/doi.org\/10.1093\/jjco\/hyn098","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"3201_CR31","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47(11):1676\u20131681. https:\/\/doi.org\/10.1016\/j.ejca.2011.04.011","journal-title":"Eur J Cancer"},{"issue":"2","key":"3201_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1743-7563.2010.01290.x","volume":"6","author":"N Hammad","year":"2010","unstructured":"Hammad N, Heilbrun LK, Philip PA et al (2010) CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol 6(2):98\u2013105. https:\/\/doi.org\/10.1111\/j.1743-7563.2010.01290.x","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"3201_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/cncr.27734","volume":"119","author":"TM Bauer","year":"2013","unstructured":"Bauer TM, El-Rayes BF, Li X et al (2013) Carbohydrate antigen 19\u20139 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 119(2):285\u2013292. https:\/\/doi.org\/10.1002\/cncr.27734","journal-title":"Cancer"},{"issue":"6","key":"3201_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ejso.2008.12.002","volume":"35","author":"JK Pine","year":"2009","unstructured":"Pine JK, Fusai KG, Young R et al (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35(6):605\u2013610. https:\/\/doi.org\/10.1016\/j.ejso.2008.12.002","journal-title":"Eur J Surg Oncol"},{"issue":"1b","key":"3201_CR35","first-page":"543","volume":"28","author":"N Papadoniou","year":"2008","unstructured":"Papadoniou N, Kosmas C, Gennatas K et al (2008) Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 28(1b):543\u2013549","journal-title":"Anticancer Res"},{"issue":"1","key":"3201_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/bjc.2013.701","volume":"110","author":"J Szkandera","year":"2014","unstructured":"Szkandera J, Stotz M, Absenger G et al (2014) Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. Br J Cancer 110(1):183\u2013188. https:\/\/doi.org\/10.1038\/bjc.2013.701","journal-title":"Br J Cancer"},{"issue":"4","key":"3201_CR37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/bjc.2012.292","volume":"107","author":"MJ Proctor","year":"2012","unstructured":"Proctor MJ, McMillan DC, Morrison DS et al (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695\u2013699. https:\/\/doi.org\/10.1038\/bjc.2012.292","journal-title":"Br J Cancer"},{"issue":"2","key":"3201_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/bjc.2013.346","volume":"109","author":"G Absenger","year":"2013","unstructured":"Absenger G, Szkandera J, Pichler M et al (2013) A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer 109(2):395\u2013400. https:\/\/doi.org\/10.1038\/bjc.2013.346","journal-title":"Br J Cancer"},{"issue":"4","key":"3201_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","volume":"19","author":"M Schwenkglenks","year":"2011","unstructured":"Schwenkglenks M, Pettengell R, Jackisch C et al (2011) Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU prospective observational European neutropenia study. Support Care Cancer 19(4):483\u2013490. https:\/\/doi.org\/10.1007\/s00520-010-0840-y","journal-title":"Support Care Cancer"},{"issue":"6","key":"3201_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1159\/000345617","volume":"58","author":"H Watanabe","year":"2012","unstructured":"Watanabe H, Ikesue H, Oshiro M et al (2012) Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. Chemotherapy 58(6):419\u2013425. https:\/\/doi.org\/10.1159\/000345617","journal-title":"Chemotherapy"},{"issue":"3","key":"3201_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00432-012-1345-5","volume":"139","author":"NL Tang","year":"2013","unstructured":"Tang NL, Liao CD, Wang X et al (2013) Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. J Cancer Res Clin Oncol 139(3):419\u2013427. https:\/\/doi.org\/10.1007\/s00432-012-1345-5","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3201_CR42","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdn560","volume":"20","author":"P Jenkins","year":"2009","unstructured":"Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20(1):34\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdn560","journal-title":"Ann Oncol"},{"issue":"8","key":"3201_CR43","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/1440-1681.12581","volume":"43","author":"ST Pan","year":"2016","unstructured":"Pan ST, Li ZL, He ZX et al (2016) Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol 43(8):723\u2013737. https:\/\/doi.org\/10.1111\/1440-1681.12581","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"3201_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02879-8","volume":"43","author":"C Bergonzini","year":"2024","unstructured":"Bergonzini C, Gregori A, Hagens TMS et al (2024) ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells. J Exp Clin Cancer Res 43(1):4. https:\/\/doi.org\/10.1186\/s13046-023-02879-8","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3201_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/cas.12560","volume":"106","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Im SA, Keam B et al (2015) ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106(1):86\u201393. https:\/\/doi.org\/10.1111\/cas.12560","journal-title":"Cancer Sci"},{"issue":"117","key":"3201_CR46","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.5754\/hge11729","volume":"59","author":"K Kasuya","year":"2012","unstructured":"Kasuya K, Tsuchida A, Nagakawa Y et al (2012) Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis. Hepatogastroenterology 59(117):1609\u20131613. https:\/\/doi.org\/10.5754\/hge11729","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"3201_CR47","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/bjc.1997.49","volume":"75","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Rissanen P et al (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75(2):301\u2013305. https:\/\/doi.org\/10.1038\/bjc.1997.49","journal-title":"Br J Cancer"},{"issue":"2","key":"3201_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00280-020-04110-3","volume":"86","author":"M Kan","year":"2020","unstructured":"Kan M, Imaoka H, Watanabe K et al (2020) Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol 86(2):203\u2013210. https:\/\/doi.org\/10.1007\/s00280-020-04110-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"107","key":"3201_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2157-7609.1000107","volume":"2","author":"D Rudin","year":"2011","unstructured":"Rudin D, Li L, Niu N et al (2011) Gemcitabine cytotoxicity: interaction of efflux and deamination. J Drug Metab Toxicol 2(107):1\u201310. https:\/\/doi.org\/10.4172\/2157-7609.1000107","journal-title":"J Drug Metab Toxicol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03201-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03201-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:16:24Z","timestamp":1789823784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03201-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":49,"alternative-id":["3201"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03201-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Masahiro Hatori reports support for professional activities from Bayer and Merck & Company, Inc., outside the submitted work. Takashi Yokokawa reports support for professional activities from Ono Pharmaceuticals outside the submitted work. Hiroshi Ishii reports support for professional activities from Chugai Pharmaceutical outside the submitted work. Masakazu Yamaguchi reports support for professional activities from AbbVie, AstraZeneca, AstraZeneca, Inc., EISAI Inc., Otsuka Pharmaceutical, Pfizer, and Terumo outside the submitted work. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN 000012720). The protocol and informed consent forms were approved by the ethics committee of each facility. Informed consent was obtained from all subjects prior to participation in the study. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has no any individual person\u2019s data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}